Class / Patent application number | Description | Number of patent applications / Date published |
536260200 | Plural phosphorus atoms in N-glycoside | 34 |
20120296076 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS - The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties. | 11-22-2012 |
20150330973 | Kits for analysis of biological samples - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens. | 11-19-2015 |
536260210 | Plural phosphorus atoms bonded directly to the same chalcogen in a chain (e.g., pyrophosphates, polyanhydrides of phosphorus acids, etc.) | 30 |
20080287671 | DRUG-ELUTING STENTS COATED WITH P2Y12 RECEPTOR ANTAGONIST COMPOUND - The present invention provides a P2Y | 11-20-2008 |
20090299048 | REACTIVE PYROPHOSPHORIC AND BISPHOSPHONIC ACID DERIVATIVES AND METHODS OF THEIR USE - This invention features bis-amides of pyrophosphoric acid and bisphosphonic acids, their preparation, and their use in synthesis of P | 12-03-2009 |
20110046362 | METHODS OF MAKING NUCLEOSIDE TETRAPHOSPHATE - The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as cystic fibrosis and upper respiratory disorders. | 02-24-2011 |
20160194347 | METHOD FOR PRODUCING P1,P4-DI(URIDINE 5'-) TETRAPHOSPHATE | 07-07-2016 |
536260220 | Both terminal phosphorus atoms are esterified by organic groups wherein one of these organic groups is the sugar moiety | 9 |
20100036110 | METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES - The invention features compositions, methods, and systems for single-molecule sequencing of nucleic acids based on the continuous measurement of the incorporation of fluorogenic nucleotides in microreactors. In particular, the invention features fluorogenic compounds for use in nucleic acid sequencing. The invention provides numerous advantages over previous systems such as unambiguous determination of sequence, continuous sequencing, long read lengths, low overall cost, and ease of sample preparation. | 02-11-2010 |
20110054163 | P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES - This invention is directed to a method of enhancing or facilitating the clearance or the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y | 03-03-2011 |
536260230 | Exactly two phosphorus atoms in the chain (e.g., coenzyme A, etc.) | 7 |
20080214800 | SIRT INHIBITORS THAT BIND TO NAD - Methods of treating sirtuin related disorders and compounds useful in treating sirtuin related disorders are described. | 09-04-2008 |
20110137023 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES - The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method a nucleophile is first dissolved in a non-aqueous solvent and dried, and a cyclosaligenyl phosphate compound is subsequently added to the solution. | 06-09-2011 |
20120041185 | dTDP-BETA-D-FUCOFURANOSE, ITS PREPARATION METHOD AND USE - Provided is a dTDP-β-D-fucofuranose, which is also referred to as dTDP-β-6-deoxy-D-galactofuranose. The dTDP-β-D-fucofuranose is synthesized by using reductase Fcf1 and mutase Fcf2 in the gram-negative bacteria. Also provided are the preparation method of the dTDP-β-D-fucofuranose and use of the dTDP-β-D-fucofuranose for manufacturing a medicament for the treatment of tumors. | 02-16-2012 |
20130102771 | NEURITE OUTGROWTH AGENT - An object of the present invention is to provide a non-peptidic nerve axon and/or neurite outgrowth agent for allowing a nerve axon and a neurite to elongate. 3-(Aminocarbonyl)-1-[5-O-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-β-D-ribofuranos-5-O-yl]phosphonyloxy(oxylato)phosphinyl]-β-L-ribofuranosyl]pyridinium that is an analogue of nicotinamide adenine dinucleotide (NAD) comprising β-L-ribose as the sugar component is used as a nerve axon and/or neurite outgrowth agent or composition, a cancer cell growth suppressing and/or apoptosis inducing agent, or a cancer cell growth suppressing and/or apoptosis inducing composition. | 04-25-2013 |
536260240 | NAD (nicotinamide adenine dinucleotide) and derivatives thereof | 3 |
20120130062 | ENZYMATIC SYNTHESIS OF CARBA-NAD - The disclosure concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide NAD/NADH and nicotinamide adenine dinucleotide phosphate NADP/NADPH, the so-called “carba-NADs”, i.e. analogues of NAD/NADH or NADP/NADPH, respectively, comprising a carbacyclic sugar instead of ribose. | 05-24-2012 |
20140142291 | ENZYMATIC SYNTHESIS OF CARBA-NAD - The disclosure concerns the enzymatic synthesis of stable analogues of nicotinamide adenine dinucleotide NAD/NADH and nicotinamide adenine dinucleotide phosphate NADP/NADPH, the so-called “carba-NADs”, i.e. analogues of NAD/NADH or NADP/NADPH, respectively, comprising a carbacyclic sugar instead of ribose. | 05-22-2014 |
20140256930 | ENZYME FUNCTION MODIFICATION METHOD AND ENZYME VARIANT THEREOF - An object of the present invention is to provide a method for converting the coenzyme dependency of enzymes of the medium-chain dehydrogenase/reductase (MDR) family. A further object of the present invention is to provide enzyme variants of the MDR family whose coenzyme dependency is converted by the conversion method and a method for enzymatically producing optically active alcohols using the enzymes. The present inventors developed a novel enzyme conversion method for converting the coenzyme dependency of enzymes of the MDR family, rationally designed enzyme variants that are altered by the enzyme conversion method to be able to use NADPH as a coenzyme from a useful enzyme of the MDR family that uses NADH as a coenzyme, and actually provide variants having such an ability. | 09-11-2014 |
536260260 | Triphosphates (in same chain) | 17 |
20080319184 | Uses of Dinucleotide Polyphosphate Derivatives - The present invention provides the use of analogues and derivatives of dinucleoside polyphosphates with formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in one or more of: the treatment of ischemia, inducing ischemic tolerance, modulating cerebral ischemia, to delay the onset of a hypoxic depolarisation stage when ischemic events are initiated; as a neurological protection agent; as a tissue protection agent; the treatment of pain; and the treatment of inflammation, wherein X, is selected from wherein X | 12-25-2008 |
20090018324 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR - Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others. | 01-15-2009 |
20090036666 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES - The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. | 02-05-2009 |
20090076256 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS - The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation. | 03-19-2009 |
20110184163 | Enzymatic Nucleic Acid Synthesis: Compositions and Methods for Inhibiting Pyrophosphorolysis - Nucleotide triphosphate probes containing a molecular and/or atomic tag on a a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed. | 07-28-2011 |
20120165515 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase - The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention. | 06-28-2012 |
20120309953 | Propargyl Substituted Nucleoside Compounds and Methods - Disclosed, among other things, are compounds having the structure | 12-06-2012 |
20130158249 | Novel Synthesis of Nucleoside 5'-Triphosphates and Their Derivatives - Disclosed are compounds of nucleoside 5′-triphosphates of formula (I), or derivatives thereof, or pharmaceutically acceptable salts of said nucleoside 5′-triphosphates or said derivatives, wherein the Base of formula (I) is Adenine (A), Cytosine (C), Guanine (G), Thymine (T), Uracil (U), modified nucleobase or unnatural nucleobase; R | 06-20-2013 |
20140051848 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING - The present invention relates generally to labeled and unlabeled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research. | 02-20-2014 |
20140058076 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 02-27-2014 |
20140179910 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 06-26-2014 |
20150376223 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 12-31-2015 |
20160016987 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 01-21-2016 |
20160039858 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 02-11-2016 |
20160039861 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs. | 02-11-2016 |
20160139133 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS - Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can vary in length in part to enable the high charge mass moiety to extend out from a DNA polymerase complex so that polymerization may not be influenced. | 05-19-2016 |
20160145292 | PHOSPHOROAMIDATE ESTERS, AND USE AND SYNTHESIS THEREOF - Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules. | 05-26-2016 |
536260300 | Plural monophosphate groups (e.g., adenosine-3`, 5`-biscarboxymethyl phosphonate, cytidine nucleoside diphosphate, etc.) | 1 |
20100152433 | ANTIVIRAL AGENT - The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are contained in a drug carrier useful for transporting a drug into a cell (e.g., cationic liposome and atelocollagen), and thus the present invention was achieved. | 06-17-2010 |
20100152433 | ANTIVIRAL AGENT - The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are contained in a drug carrier useful for transporting a drug into a cell (e.g., cationic liposome and atelocollagen), and thus the present invention was achieved. | 06-17-2010 |
536260300 | Plural monophosphate groups (e.g., adenosine-3, 5-biscarboxymethyl phosphonate, cytidine nucleoside diphosphate, etc.) | 1 |
20100152433 | ANTIVIRAL AGENT - The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are contained in a drug carrier useful for transporting a drug into a cell (e.g., cationic liposome and atelocollagen), and thus the present invention was achieved. | 06-17-2010 |
20100152433 | ANTIVIRAL AGENT - The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are contained in a drug carrier useful for transporting a drug into a cell (e.g., cationic liposome and atelocollagen), and thus the present invention was achieved. | 06-17-2010 |